DIVA Laboratories, Ltd. (TPEX:4153)
Taiwan · Delayed Price · Currency is TWD 33.00
0.00 (0.00%)
Aug 18, 2026, 1:30 PM CST
DIVA Laboratories Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 894.67 | 868.84 | 862.32 | 893.84 | 949.2 | 712.23 | |
Revenue Growth | 4.15% | 0.76% | -3.53% | -5.83% | 33.27% | -3.35% |
Cost of Revenue | 637.02 | 604.7 | 602.14 | 643.07 | 683.07 | 530.64 |
Gross Profit | 257.66 | 264.14 | 260.18 | 250.77 | 266.13 | 181.6 |
Selling, General & Admin | 82.88 | 82.31 | 85.71 | 85.01 | 97.7 | 88.18 |
Research & Development | 74.59 | 72.46 | 71.9 | 69.16 | 82.62 | 69.52 |
Other Operating Expenses | -1.55 | -0.54 | 0.28 | -2.17 | 0.46 | -0.18 |
Operating Expenses | 157.93 | 161.89 | 149.01 | 158.62 | 181.3 | 158.99 |
Operating Income | 99.72 | 102.26 | 111.17 | 92.15 | 84.83 | 22.6 |
Interest Expense | -0.44 | -0.24 | -0.21 | -0.33 | -0.2 | -0.11 |
Interest & Investment Income | 5.53 | 6.18 | 5.8 | 4.37 | 0.76 | 0.53 |
Earnings From Equity Investments | 1.73 | 1.67 | 1.71 | -7.16 | -1.03 | 2.16 |
Currency Exchange Gain (Loss) | -10.12 | -10.12 | 14.7 | -17.07 | -2.14 | -11.16 |
Other Non Operating Income (Expenses) | -8.85 | -13.45 | -11.09 | 6.66 | 8.39 | 11.15 |
EBT Excluding Unusual Items | 87.57 | 86.29 | 122.09 | 78.63 | 90.62 | 25.18 |
Impairment of Goodwill | - | - | - | - | -5.18 | - |
Gain (Loss) on Sale of Investments | 22.48 | 22.48 | -6.14 | 9.21 | -17.34 | 0.44 |
Gain (Loss) on Sale of Assets | -0.02 | -0.02 | - | -0.07 | 0.93 | 2.85 |
Asset Writedown | - | - | - | - | -1.38 | - |
Pretax Income | 110.03 | 108.75 | 115.95 | 87.77 | 67.64 | 28.47 |
Income Tax Expense | 14.03 | 18.21 | 22.29 | 14.15 | 17.98 | 6.61 |
Net Income | 95.99 | 90.54 | 93.66 | 73.62 | 49.66 | 21.86 |
Net Income to Common | 95.99 | 90.54 | 93.66 | 73.62 | 49.66 | 21.86 |
Net Income Growth | 7.93% | -3.33% | 27.23% | 48.24% | 127.23% | 25.47% |
Shares Outstanding (Basic) | 58 | 59 | 59 | 59 | 59 | 59 |
Shares Outstanding (Diluted) | 59 | 59 | 59 | 59 | 59 | 59 |
Shares Change | 0.14% | 0.02% | 0.03% | 0.13% | 0.07% | -11.69% |
EPS (Basic) | 1.64 | 1.54 | 1.60 | 1.25 | 0.85 | 0.37 |
EPS (Diluted) | 1.63 | 1.54 | 1.59 | 1.25 | 0.84 | 0.37 |
EPS Growth | 7.96% | -3.15% | 27.20% | 48.81% | 127.03% | 42.31% |
Free Cash Flow | 18.81 | 19.89 | 121.63 | 245.43 | 62.84 | -23.53 |
Free Cash Flow Per Share | 0.32 | 0.34 | 2.06 | 4.17 | 1.07 | -0.40 |
Dividend Per Share | 2.000 | 2.000 | 2.000 | 1.250 | 1.000 | 0.370 |
Dividend Growth | 0% | 0% | 60.00% | 25.00% | 170.27% | 42.31% |
Gross Margin | 28.80% | 30.40% | 30.17% | 28.06% | 28.04% | 25.50% |
Operating Margin | 11.15% | 11.77% | 12.89% | 10.31% | 8.94% | 3.17% |
Profit Margin | 10.73% | 10.42% | 10.86% | 8.24% | 5.23% | 3.07% |
Free Cash Flow Margin | 2.10% | 2.29% | 14.11% | 27.46% | 6.62% | -3.30% |
EBITDA | 106.3 | 109.03 | 118.67 | 100.32 | 93.06 | 34.05 |
EBITDA Margin | 11.88% | 12.55% | 13.76% | 11.22% | 9.80% | 4.78% |
D&A For EBITDA | 6.58 | 6.77 | 7.5 | 8.17 | 8.23 | 11.44 |
EBIT | 99.72 | 102.26 | 111.17 | 92.15 | 84.83 | 22.6 |
EBIT Margin | 11.15% | 11.77% | 12.89% | 10.31% | 8.94% | 3.17% |
Effective Tax Rate | 12.75% | 16.74% | 19.22% | 16.12% | 26.58% | 23.23% |